{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:10:54Z","timestamp":1790799054952,"version":"4.1.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T00:00:00Z","timestamp":1598486400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T00:00:00Z","timestamp":1598486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["167280"],"award-info":[{"award-number":["167280"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Toxicol"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s00204-020-02876-2","type":"journal-article","created":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T05:02:26Z","timestamp":1598504546000},"page":"1-9","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["The beneficial effects of reducing NLRP3 inflammasome activation in the cardiotoxicity and the anti-cancer effects of doxorubicin"],"prefix":"10.1007","volume":"95","author":[{"given":"Zaid H.","family":"Maayah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Takahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7045-2884","authenticated-orcid":false,"given":"Jason R. B.","family":"Dyck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,27]]},"reference":[{"issue":"7","key":"2876_CR1","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.cardfail.2015.04.014","volume":"21","author":"B Butts","year":"2015","unstructured":"Butts B, Gary RA, Dunbar SB, Butler J (2015) The Importance of NLRP3 Inflammasome in Heart Failure. J Card Fail 21(7):586\u2013593. https:\/\/doi.org\/10.1016\/j.cardfail.2015.04.014","journal-title":"J Card Fail"},{"issue":"1","key":"2876_CR2","doi-asserted-by":"publisher","first-page":"e006277","DOI":"10.1161\/CIRCHEARTFAILURE.119.006277","volume":"13","author":"NJ Byrne","year":"2020","unstructured":"Byrne NJ, Matsumura N, Maayah ZH et al (2020) Empagliflozin blunts worsening cardiac dysfunction associated with reduced NLRP3 (Nucleotide-Binding Domain-Like Receptor Protein 3) inflammasome activation in heart failure. Circ Heart Fail 13(1):e006277. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.119.006277","journal-title":"Circ Heart Fail"},{"issue":"2","key":"2876_CR3","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1159\/000265166","volume":"115","author":"K Chatterjee","year":"2010","unstructured":"Chatterjee K, Zhang J, Honbo N, Karliner JS (2010) Doxorubicin cardiomyopathy. Cardiology 115(2):155\u2013162. https:\/\/doi.org\/10.1159\/000265166","journal-title":"Cardiology"},{"issue":"6","key":"2876_CR4","doi-asserted-by":"publisher","first-page":"1903616","DOI":"10.1002\/advs.201903616","volume":"7","author":"Q Chen","year":"2020","unstructured":"Chen Q, Lei JH, Bao J et al (2020) BRCA1 deficiency impairs mitophagy and promotes inflammasome activation and mammary tumor metastasis. Adv Sci 7(6):1903616. https:\/\/doi.org\/10.1002\/advs.201903616","journal-title":"Adv Sci"},{"key":"2876_CR5","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1186\/1471-2407-14-842","volume":"14","author":"S Deng","year":"2014","unstructured":"Deng S, Yan T, Jendrny C et al (2014) Dexrazoxane may prevent doxorubicin-induced DNA damage via depleting both topoisomerase II isoforms. BMC cancer 14:842. https:\/\/doi.org\/10.1186\/1471-2407-14-842","journal-title":"BMC cancer"},{"key":"2876_CR6","doi-asserted-by":"publisher","first-page":"281","DOI":"10.3389\/fonc.2020.00281","volume":"10","author":"MA Desbats","year":"2020","unstructured":"Desbats MA, Giacomini I, Prayer-Galetti T, Montopoli M (2020) Metabolic plasticity in chemotherapy resistance. Front Oncol 10:281. https:\/\/doi.org\/10.3389\/fonc.2020.00281","journal-title":"Front Oncol"},{"issue":"1","key":"2876_CR7","doi-asserted-by":"publisher","first-page":"4375","DOI":"10.1038\/s41467-019-12370-8","volume":"10","author":"N Ershaid","year":"2019","unstructured":"Ershaid N, Sharon Y, Doron H et al (2019) NLRP3 inflammasome in fibroblasts links tissue damage with inflammation in breast cancer progression and metastasis. Nat Commun 10(1):4375. https:\/\/doi.org\/10.1038\/s41467-019-12370-8","journal-title":"Nat Commun"},{"issue":"15","key":"2876_CR8","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1056\/NEJM200004133421502","volume":"342","author":"GM Felker","year":"2000","unstructured":"Felker GM, Thompson RE, Hare JM et al (2000) Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. NEngl J Med 342(15):1077\u20131084. https:\/\/doi.org\/10.1056\/NEJM200004133421502","journal-title":"NEngl J Med"},{"issue":"3","key":"2876_CR9","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/ni.1703","volume":"10","author":"L Franchi","year":"2009","unstructured":"Franchi L, Eigenbrod T, Munoz-Planillo R, Nunez G (2009) The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis. Nat Immunol 10(3):241\u2013247. https:\/\/doi.org\/10.1038\/ni.1703","journal-title":"Nat Immunol"},{"key":"2876_CR10","doi-asserted-by":"publisher","first-page":"36107","DOI":"10.1038\/srep36107","volume":"6","author":"B Guo","year":"2016","unstructured":"Guo B, Fu S, Zhang J, Liu B, Li Z (2016) Targeting inflammasome\/IL-1 pathways for cancer immunotherapy. Sci Rep 6:36107. https:\/\/doi.org\/10.1038\/srep36107","journal-title":"Sci Rep"},{"issue":"2","key":"2876_CR11","doi-asserted-by":"publisher","first-page":"H499","DOI":"10.1152\/ajpheart.00047.2003","volume":"285","author":"S Heon","year":"2003","unstructured":"Heon S, Bernier M, Servant N et al (2003) Dexrazoxane does not protect against doxorubicin-induced damage in young rats. Am J Physiol Heart Circ Physiol 285(2):H499\u2013506. https:\/\/doi.org\/10.1152\/ajpheart.00047.2003","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"46","key":"2876_CR12","doi-asserted-by":"publisher","first-page":"75571","DOI":"10.18632\/oncotarget.12289","volume":"7","author":"I Holen","year":"2016","unstructured":"Holen I, Lefley DV, Francis SE et al (2016) IL-1 drives breast cancer growth and bone metastasis in vivo. Oncotarget 7(46):75571\u201375584. https:\/\/doi.org\/10.18632\/oncotarget.12289","journal-title":"Oncotarget"},{"issue":"1\u20132","key":"2876_CR13","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1006\/mgme.2000.3043","volume":"71","author":"MS Horenstein","year":"2000","unstructured":"Horenstein MS, Vander Heide RS, L'Ecuyer TJ (2000) Molecular basis of anthracycline-induced cardiotoxicity and its prevention. Mol Genet Metab 71(1\u20132):436\u2013444. https:\/\/doi.org\/10.1006\/mgme.2000.3043","journal-title":"Mol Genet Metab"},{"issue":"1","key":"2876_CR14","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1161\/01.res.84.1.21","volume":"84","author":"DJ Ing","year":"1999","unstructured":"Ing DJ, Zang J, Dzau VJ, Webster KA, Bishopric NH (1999) Modulation of cytokine-induced cardiac myocyte apoptosis by nitric oxide, Bak, and Bcl-x. Circ Res 84(1):21\u201333. https:\/\/doi.org\/10.1161\/01.res.84.1.21","journal-title":"Circ Res"},{"key":"2876_CR15","doi-asserted-by":"publisher","first-page":"e217","DOI":"10.1038\/emm.2016.20","volume":"48","author":"JW Jahng","year":"2016","unstructured":"Jahng JW, Song E, Sweeney G (2016) Crosstalk between the heart and peripheral organs in heart failure. Exp Mol Med 48:e217. https:\/\/doi.org\/10.1038\/emm.2016.20","journal-title":"Exp Mol Med"},{"issue":"21","key":"2876_CR16","doi-asserted-by":"publisher","first-page":"12610","DOI":"10.1074\/jbc.271.21.12610","volume":"271","author":"YJ Kang","year":"1996","unstructured":"Kang YJ, Chen Y, Epstein PN (1996) Suppression of doxorubicin cardiotoxicity by overexpression of catalase in the heart of transgenic mice. J Biol Chem 271(21):12610\u201312616","journal-title":"J Biol Chem"},{"key":"2876_CR17","doi-asserted-by":"publisher","first-page":"26489","DOI":"10.1038\/srep26489","volume":"6","author":"M Kobayashi","year":"2016","unstructured":"Kobayashi M, Usui F, Karasawa T et al (2016) NLRP3 deficiency reduces macrophage interleukin-10 production and enhances the susceptibility to doxorubicin-induced cardiotoxicity. Sci Rep 6:26489. https:\/\/doi.org\/10.1038\/srep26489","journal-title":"Sci Rep"},{"issue":"3","key":"2876_CR18","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1200\/JCO.2004.03.086","volume":"22","author":"EJ Ladas","year":"2004","unstructured":"Ladas EJ, Jacobson JS, Kennedy DD, Teel K, Fleischauer A, Kelly KM (2004) Antioxidants and cancer therapy: a systematic review. J Clin Oncol Off J Am Soc Clin Oncol 22(3):517\u2013528. https:\/\/doi.org\/10.1200\/JCO.2004.03.086","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"6","key":"2876_CR19","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/sj.bjp.0707294","volume":"151","author":"D Lebrecht","year":"2007","unstructured":"Lebrecht D, Geist A, Ketelsen UP, Haberstroh J, Setzer B, Walker UA (2007) Dexrazoxane prevents doxorubicin-induced long-term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats. Br J Pharmacol 151(6):771\u2013778. https:\/\/doi.org\/10.1038\/sj.bjp.0707294","journal-title":"Br J Pharmacol"},{"key":"2876_CR20","doi-asserted-by":"publisher","first-page":"866","DOI":"10.3389\/fphys.2019.00866","volume":"10","author":"X Li","year":"2019","unstructured":"Li X, Geng J, Zhao J et al (2019) Trimethylamine N-oxide exacerbates cardiac fibrosis via activating the NLRP3 inflammasome. Front Physiol 10:866. https:\/\/doi.org\/10.3389\/fphys.2019.00866","journal-title":"Front Physiol"},{"issue":"2","key":"2876_CR21","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1056\/NEJMoa035153","volume":"351","author":"SE Lipshultz","year":"2004","unstructured":"Lipshultz SE, Rifai N, Dalton VM et al (2004) The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. NEngl J Med 351(2):145\u2013153. https:\/\/doi.org\/10.1056\/NEJMoa035153","journal-title":"NEngl J Med"},{"issue":"11","key":"2876_CR22","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1161\/01.res.0000043825.01705.1b","volume":"91","author":"DL Mann","year":"2002","unstructured":"Mann DL (2002) Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res 91(11):988\u2013998. https:\/\/doi.org\/10.1161\/01.res.0000043825.01705.1b","journal-title":"Circ Res"},{"issue":"4","key":"2876_CR23","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1097\/FJC.0000000000000053","volume":"63","author":"C Marchetti","year":"2014","unstructured":"Marchetti C, Chojnacki J, Toldo S et al (2014) A novel pharmacologic inhibitor of the NLRP3 inflammasome limits myocardial injury after ischemia-reperfusion in the mouse. J Cardiovasc Pharmacol 63(4):316\u2013322. https:\/\/doi.org\/10.1097\/FJC.0000000000000053","journal-title":"J Cardiovasc Pharmacol"},{"issue":"1","key":"2876_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/FJC.0000000000000247","volume":"66","author":"C Marchetti","year":"2015","unstructured":"Marchetti C, Toldo S, Chojnacki J et al (2015) Pharmacologic inhibition of the NLRP3 inflammasome preserves cardiac function after ischemic and nonischemic injury in the mouse. J Cardiovasc Pharmacol 66(1):1\u20138. https:\/\/doi.org\/10.1097\/FJC.0000000000000247","journal-title":"J Cardiovasc Pharmacol"},{"issue":"10","key":"2876_CR25","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.1200\/JCO.2001.19.10.2746","volume":"19","author":"MT Meinardi","year":"2001","unstructured":"Meinardi MT, van Veldhuisen DJ, Gietema JA et al (2001) Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients. J Clin Oncol Off J Am Soc Clin Oncol 19(10):2746\u20132753. https:\/\/doi.org\/10.1200\/JCO.2001.19.10.2746","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2876_CR26","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.canlet.2017.01.005","volume":"390","author":"M Mendoza-Rodriguez","year":"2017","unstructured":"Mendoza-Rodriguez M, Arevalo Romero H, Fuentes-Panana EM, Ayala-Sumuano JT, Meza I (2017) IL-1beta induces up-regulation of BIRC3, a gene involved in chemoresistance to doxorubicin in breast cancer cells. Cancer Lett 390:39\u201344. https:\/\/doi.org\/10.1016\/j.canlet.2017.01.005","journal-title":"Cancer Lett"},{"issue":"49","key":"2876_CR27","doi-asserted-by":"publisher","first-page":"19725","DOI":"10.1073\/pnas.1108586108","volume":"108","author":"E Mezzaroma","year":"2011","unstructured":"Mezzaroma E, Toldo S, Farkas D et al (2011) The inflammasome promotes adverse cardiac remodeling following acute myocardial infarction in the mouse. Proc Natl Acad Sci USA 108(49):19725\u201319730. https:\/\/doi.org\/10.1073\/pnas.1108586108","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"2876_CR28","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1124\/pr.56.2.6","volume":"56","author":"G Minotti","year":"2004","unstructured":"Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L (2004) Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56(2):185\u2013229. https:\/\/doi.org\/10.1124\/pr.56.2.6","journal-title":"Pharmacol Rev"},{"issue":"18","key":"2876_CR29","doi-asserted-by":"publisher","first-page":"3700","DOI":"10.1200\/JCO.2004.03.516","volume":"22","author":"EA Perez","year":"2004","unstructured":"Perez EA, Suman VJ, Davidson NE et al (2004) Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial. J Clin Oncol Off J Am Soc Clin Oncol 22(18):3700\u20133704. https:\/\/doi.org\/10.1200\/JCO.2004.03.516","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"12","key":"2876_CR30","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","volume":"377","author":"PM Ridker","year":"2017","unstructured":"Ridker PM, Everett BM, Thuren T et al (2017) Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 377(12):1119\u20131131. https:\/\/doi.org\/10.1056\/NEJMoa1707914","journal-title":"N Engl J Med"},{"issue":"12","key":"2876_CR31","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.4161\/cbt.11.12.15540","volume":"11","author":"KA Sauter","year":"2011","unstructured":"Sauter KA, Wood LJ, Wong J, Iordanov M, Magun BE (2011) Doxorubicin and daunorubicin induce processing and release of interleukin-1beta through activation of the NLRP3 inflammasome. Cancer Biol Ther 11(12):1008\u20131016. https:\/\/doi.org\/10.4161\/cbt.11.12.15540","journal-title":"Cancer Biol Ther"},{"issue":"4","key":"2876_CR32","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1002\/pbc.25043","volume":"62","author":"AE Seif","year":"2015","unstructured":"Seif AE, Walker DM, Li Y et al (2015) Dexrazoxane exposure and risk of secondary acute myeloid leukemia in pediatric oncology patients. Pediatr Blood Cancer 62(4):704\u2013709. https:\/\/doi.org\/10.1002\/pbc.25043","journal-title":"Pediatr Blood Cancer"},{"issue":"1\u20132","key":"2876_CR33","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s11010-005-5905-8","volume":"273","author":"Y Shizukuda","year":"2005","unstructured":"Shizukuda Y, Matoba S, Mian OY, Nguyen T, Hwang PM (2005) Targeted disruption of p53 attenuates doxorubicin-induced cardiac toxicity in mice. Mol Cell Biochem 273(1\u20132):25\u201332","journal-title":"Mol Cell Biochem"},{"issue":"7381","key":"2876_CR34","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/nature10759","volume":"481","author":"T Strowig","year":"2012","unstructured":"Strowig T, Henao-Mejia J, Elinav E, Flavell R (2012) Inflammasomes in health and disease. Nature 481(7381):278\u2013286. https:\/\/doi.org\/10.1038\/nature10759","journal-title":"Nature"},{"key":"2876_CR35","doi-asserted-by":"publisher","first-page":"113888","DOI":"10.1016\/j.bcp.2020.113888","volume":"175","author":"Z Sun","year":"2020","unstructured":"Sun Z, Lu W, Lin N et al (2020) Dihydromyricetin alleviates doxorubicin-induced cardiotoxicity by inhibiting NLRP3 inflammasome through activation of SIRT1. Biochem Pharmacol 175:113888. https:\/\/doi.org\/10.1016\/j.bcp.2020.113888","journal-title":"Biochem Pharmacol"},{"issue":"5","key":"2876_CR36","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.pcad.2006.10.002","volume":"49","author":"G Takemura","year":"2007","unstructured":"Takemura G, Fujiwara H (2007) Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. Prog Cardiovasc Dis 49(5):330\u2013352. https:\/\/doi.org\/10.1016\/j.pcad.2006.10.002","journal-title":"Prog Cardiovasc Dis"},{"issue":"5","key":"2876_CR37","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1200\/JCO.2005.02.3879","volume":"25","author":"CK Tebbi","year":"2007","unstructured":"Tebbi CK, London WB, Friedman D et al (2007) Dexrazoxane-associated risk for acute myeloid leukemia\/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease. J Clin Oncol Off J Am Soc Clin Oncol 25(5):493\u2013500. https:\/\/doi.org\/10.1200\/JCO.2005.02.3879","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"4","key":"2876_CR38","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.jacbts.2017.07.006","volume":"2","author":"S Toldo","year":"2017","unstructured":"Toldo S, Van Tassell BW, Abbate A (2017) Interleukin-1 blockade in acute myocardial infarction and heart failure: getting closer and closer. JACC Basic Transl Sci 2(4):431\u2013433. https:\/\/doi.org\/10.1016\/j.jacbts.2017.07.006","journal-title":"JACC Basic Transl Sci"},{"issue":"8","key":"2876_CR39","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1016\/j.amjcard.2018.07.002","volume":"122","author":"CR Trankle","year":"2018","unstructured":"Trankle CR, Canada JM, Cei L et al (2018) Usefulness of canakinumab to improve exercise capacity in patients with long-term systolic heart failure and elevated C-reactive protein. Am J Cardiol 122(8):1366\u20131370. https:\/\/doi.org\/10.1016\/j.amjcard.2018.07.002","journal-title":"Am J Cardiol"},{"issue":"11","key":"2876_CR40","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/S1470-2045(05)70424-1","volume":"6","author":"M Trudeau","year":"2005","unstructured":"Trudeau M, Charbonneau F, Gelmon K et al (2005) Selection of adjuvant chemotherapy for treatment of node-positive breast cancer. Lancet Oncol 6(11):886\u2013898. https:\/\/doi.org\/10.1016\/S1470-2045(05)70424-1","journal-title":"Lancet Oncol"},{"issue":"9","key":"2876_CR41","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1158\/1078-0432.CCR-18-2202","volume":"25","author":"C Tulotta","year":"2019","unstructured":"Tulotta C, Lefley DV, Freeman K et al (2019) Endogenous production of IL1B by breast cancer cells drives metastasis and colonization of the bone microenvironment. Clin Cancer Res Off J Am Assoc Cancer Res 25(9):2769\u20132782. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-2202","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"3","key":"2876_CR42","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s10555-006-9013-3","volume":"25","author":"F Vidal-Vanaclocha","year":"2006","unstructured":"Vidal-Vanaclocha F, Mendoza L, Telleria N et al (2006) Clinical and experimental approaches to the pathophysiology of interleukin-18 in cancer progression. Cancer Metastasis Rev 25(3):417\u2013434. https:\/\/doi.org\/10.1007\/s10555-006-9013-3","journal-title":"Cancer Metastasis Rev"},{"issue":"2","key":"2876_CR43","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1124\/mol.119.115725","volume":"96","author":"N Wenningmann","year":"2019","unstructured":"Wenningmann N, Knapp M, Ande A, Vaidya TR, Ait-Oudhia S (2019) Insights into doxorubicin-induced cardiotoxicity: molecular mechanisms, preventive strategies, and early monitoring. Mol Pharmacol 96(2):219\u2013232. https:\/\/doi.org\/10.1124\/mol.119.115725","journal-title":"Mol Pharmacol"},{"issue":"10","key":"2876_CR44","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.4161\/cbt.29922","volume":"15","author":"J Wong","year":"2014","unstructured":"Wong J, Tran LT, Magun EA, Magun BE, Wood LJ (2014) Production of IL-1beta by bone marrow-derived macrophages in response to chemotherapeutic drugs: synergistic effects of doxorubicin and vincristine. Cancer Biol Ther 15(10):1395\u20131403. https:\/\/doi.org\/10.4161\/cbt.29922","journal-title":"Cancer Biol Ther"},{"issue":"9","key":"2876_CR45","doi-asserted-by":"publisher","first-page":"e24684","DOI":"10.1371\/journal.pone.0024684","volume":"6","author":"L Yao","year":"2011","unstructured":"Yao L, Zhang Y, Chen K, Hu X, Xu LX (2011) Discovery of IL-18 as a novel secreted protein contributing to doxorubicin resistance by comparative secretome analysis of MCF-7 and MCF-7\/Dox. PLoS ONE 6(9):e24684. https:\/\/doi.org\/10.1371\/journal.pone.0024684","journal-title":"PLoS ONE"},{"issue":"5","key":"2876_CR46","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1172\/JCI118909","volume":"98","author":"HC Yen","year":"1996","unstructured":"Yen HC, Oberley TD, Vichitbandha S, Ho YS, St Clair DK (1996) The protective role of manganese superoxide dismutase against adriamycin-induced acute cardiac toxicity in transgenic mice. J Clin Investig 98(5):1253\u20131260. https:\/\/doi.org\/10.1172\/JCI118909","journal-title":"J Clin Investig"},{"issue":"3","key":"2876_CR47","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.3892\/mmr.2019.9889","volume":"19","author":"L Zhang","year":"2019","unstructured":"Zhang L, Li H, Zang Y, Wang F (2019) NLRP3 inflammasome inactivation driven by miR2233p reduces tumor growth and increases anticancer immunity in breast cancer. Mol Med Rep 19(3):2180\u20132188. https:\/\/doi.org\/10.3892\/mmr.2019.9889","journal-title":"Mol Med Rep"},{"issue":"2\u20133","key":"2876_CR48","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.ejphar.2010.06.024","volume":"643","author":"J Zhu","year":"2010","unstructured":"Zhu J, Zhang J, Xiang D et al (2010) Recombinant human interleukin-1 receptor antagonist protects mice against acute doxorubicin-induced cardiotoxicity. Eur J Pharmacol 643(2\u20133):247\u2013253. https:\/\/doi.org\/10.1016\/j.ejphar.2010.06.024","journal-title":"Eur J Pharmacol"},{"issue":"7","key":"2876_CR49","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.biopha.2011.06.005","volume":"65","author":"J Zhu","year":"2011","unstructured":"Zhu J, Zhang J, Zhang L et al (2011) Interleukin-1 signaling mediates acute doxorubicin-induced cardiotoxicity. Biomed Pharmacother 65(7):481\u2013485. https:\/\/doi.org\/10.1016\/j.biopha.2011.06.005","journal-title":"Biomed Pharmacother"}],"container-title":["Archives of Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00204-020-02876-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00204-020-02876-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00204-020-02876-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,26]],"date-time":"2021-08-26T23:32:10Z","timestamp":1630020730000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00204-020-02876-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,27]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["2876"],"URL":"https:\/\/doi.org\/10.1007\/s00204-020-02876-2","relation":{},"ISSN":["0340-5761","1432-0738"],"issn-type":[{"value":"0340-5761","type":"print"},{"value":"1432-0738","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,27]]},"assertion":[{"value":"12 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}